Lipid profile of ambulatory patients with type 2 diabetes mellitus at Kenyatta National Hospital, Nairobi

East African Medical Journal

Volumn 82, Issue 12 SUPPL., 2005, Pages

  Otieno, C F ^a   Mwendwa, F W ^b   Vaghela, V ^c   Ogola, E N ^a   Amayo, E O ^a  

^a UNIVERSITY OF NAIROBI   (Kenya)

^b Upper Hill Medical Centre   (Kenya)

^c Department of Obstetrics and Gynaecology   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; LIPID;

ARTICLE; BLOOD; BODY MASS; CROSS-SECTIONAL STUDY; DYSLIPIDEMIA; FEMALE; HUMAN; KENYA; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT DEPARTMENT; PATHOPHYSIOLOGY; PROSPECTIVE STUDY;

BODY MASS INDEX; CHOLESTEROL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; HUMANS; KENYA; LIPIDS; MALE; MIDDLE AGED; OUTPATIENT CLINICS, HOSPITAL; PROSPECTIVE STUDIES;

EID: 33644608022     PISSN: 0012835X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Castelli, W.P., Garrison, R.J., Wilson, P.W.F., et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA. 1986; 256: 2835-2838.
2. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. I: reduction in the incidence of Coronary Heart Disease. JAMA. 1984; 251: 351-364.
3. The WOSCOPS study group. West of Scotland coronary prevention study: implications for clinical practice. Eur. Heart J. 1996; 17: 163-164.
4. Sacks, F.M., Pfeffer, M.A., Moye, L.A. et al. For the cholesterol and recurrent events investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Eng. J. Med. 1996; 335: 1001-1009.
5. Wilson, P.W.F. Diabetes and coronary heart disease. Endocrinol. Metabol. Clin. 2001; 30: 857-881.
6. Superko, H.R. Lipoprotein subclasses and atherosclerosis. Front Biosc. 2001; 6: D355-D365.
7. Buse, J.D. Lipid changes associated with diabetes therapy. Practical diabetology. 2003; 24-29.
8. Austin, M.A. and Edwards, K.L. Small, dense low-density lipoproteins, the insulin resistance syndrome and non-insulin dependent diabetes. Curr. Opin. Lipidol. 1996; 7: 167-171.
9. Kreisberg, R.A. Diabetic dyslipidaemia. Amer. J. Cardiol. 1998; 82: 67U-73U
10. Bays, H.E. Existing and investigational combination drug therapy for high density lipoprotein cholesterol. Amer. J. Cardiol. 2002; 90(suppl): 30k-43k.
11. World Health Organization: Definition, diagnosis and classification of diabetes mellitus and its complications report of WHO consultation part I: Diagnosis and classification of diabetes mellitus. Geneva, 1999.
12. ADA Management of dyslipidaemia in adults with diabetes. Diabetes Care. 2002; 25: 574-577.
13. McNamara, J.R. and Schaefer, E.J. Automated enzymatic standardized lipid analysis for plasma and lipid lipoprotein fractions. Clin. Chem. Acta. 1987; 166: 1-8.
14. Friedewald, R., Levy, R.I. and Fredrickson, D.S. Estimation of the concentration of LDL-C in plasma without the use of preparative ultracentrifuge. Clin. Chem. 1972; 18: 499-502.
15. Joslin, E.P. Ann. Clin. Med. 1927; 5: 1061
16. Chait, A. and Brunzell, J.D. Lipids and Lipoproteins. In: G. Michael Besser and Michael O Thorner. Comprehensive Clinical Endocrinology. 3rd Edition, 2002. Elsevier Science Ltd. Pp. 471-484.
17. Taskinen, M-R., Lahdenpera, S. and Syvanne, M. New insights into lipid metabolism in non-insulin dependent diabetes mellitus. Ann. Med. 1996; 28: 335-340.
18. Chen, Y-D.I., Swami, S., Skowronski, R. et al. Differences in post-prandial Lipaemia between patients with NGT and NIDDM. J. Clin. Endocrinol. Metab. 1993; 76: 172-177.
19. Betteridge, D.J. Diabetic dyslipidaemia. Amer. J. Med. 1994; 96(suppl 6A): 25S-31S.
20. Tkac, I., Kimball, B.P. and Lewis, G. et al. The severity of coronary atherosclerosis in type 2 diabetes mellitus is related to the number of circulating triglyceride-rich lipoprotein particles. Arterioscler. Thromb. Vasc. Biol. 1997; 17: 3633-3638.
21. McNamara, J.R., Campos, H., Ordovas, J.M. et al. Effect of gender, age and lipid status on low-density lipoprotein sub-fraction distribution. Results from the Framingham offspring study. Arteriosclerosis. 1987; 7: 483-490.
22. Law, M.R. and Wald, N.J. Risk factor thresholds: their existence under scrutiny. Brit. Med. J. 2002; 324: 1570-1576.
23. Rubins, H.B., Robins, S.J., Collins, D. et al. For VA-HIT study group. Gemfibrozil for secondary prevention of coronary heart disease in men with low high density lipoprotein cholesterol. N. Eng. J. Med. 1999; 341: 410-418.
24. Hokanson, J.E. and Austin, M.E. Plasma TG level is a risk factor for cardiovascular disease independent of HDL-C: a meta-analysis of population-based prospective studies. J. Cardiovasc. Risk. 1996; 3: 213-219.
25. Pyoralo, K., Pedersen, T.R., Kjekshus, J. et al. Cholesterol-lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a sub-analysis of Scandinavian simvastatin survival study 45. Diab Care. 1997; 20: 614-620.
26. Collins, R., Armitage, J., Parish, S. et al. Heart protection study collaborative group: MRC/BHF Heart Protection study of cholesterol-lowering with Simvastatin in 5963 people with diabetes: a randomized place be-controlled trial. Lancet. 2003; 361: 2005-2016.
27. Fornengo, P., Bruno, G., DeSalvia, A. et al. Low adherence of General Practitioners to NCEP guidelines for the management of hyperlipidaemia. Diab. Nutr. Metabol. 2000; 13: 263-268.
28. Garber, A.J. and Karlsson, F.O. Treatment of dyslipidaemia in diabetes. Endocrinol. Metab. Clin. North Amer. 2001; 30: 999-1010.
29. Galton, D. Lipid lowering drug therapies. In: Galto D. J. In: Clinical Practice Series:Dyslipidaemia. 2003 Edition. Churchill Livingstone. Elsevier Ltd. Spain. Pp 81.
30. Krans, W.E., Hourmard, J.A., Duscha, B.D. et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N. Eng. J. Med. 2002; 347: 1483-1492.
31. Barret-Connor, E., Grundy, S.M. and Holbrook J.J. Plasma lipids and diabetes mellitus in an adult community. Amer. J. Epidemiol. 1982; 115: 657-663.
32. Wilson, P.W., Kannel, W.B. and Anderson, K.M. Lipids, glucose tolerance and vascular disease: the Framingham Study. Monogr. Atheroscler. 1985; 13: 1-11.
33. Pyorala, K. Interpopulation correlations between serum cholesterol level and the occurrence of Coronary Heart Disease. Eur. Heart J. 1987; 8 (suppl E): 23-30.
34. Jousilhati, P., Vartiaineu, E., Pekkanen, J. et al. Serum cholesterol distribution and coronary artery disease risk: observations and predictions among middle-aged population in Eastern Finland. Circulation. 1998; 97: 1087-1094.